A Ph.D. position within formulation characterization focused on stability investigations of pharmaceutical suspensions is available at theDepartment of Physics Chemistry and Pharmacyin the pharmacy research group.
Project background
Terminal sterilization is the process of sterilizing a pharmaceutical product in its final container. Among various sterilization techniques moist heat sterilization (autoclaving at 121C) is the most widely accepted and validated method due to its proven microbial lethality cost-effectiveness and ease of implementation at scale- Other options are gamma radiation and E-beam. Regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) strongly prefer terminal sterilization over aseptic manufacturing wherever feasible as it offers a higher Sterility Assurance Level (SAL) and significantly reduces the risk of post-process contamination.
Despite its advantages terminal sterilization is not universally applicable. A significant limitation arises when drug substances or drug formulations are thermolabile meaning they degrade either chemically or physically upon exposure to high temperatures. This is especially problematic for colloidal based formulations such as suspensions intended for injection which also cannot be sterile filtrated. Terminal sterilization of suspensions can lead to aggregation hydrolysis oxidation Ostwald riepening or other chemical and physical degradation pathways. As a result most marketed parenteral suspension products are manufactured using aseptic processing where the drug and container are sterilized separately and then combined under aseptic conditions. Although effective aseptic processing introduces significant operational complexity requires extensive environmental controls is more costly and presents a higher risk of microbial contamination.
To stabilize the inherently thermodynamic instable suspensions addition of surfactants to stabilize the formulation is often needed. These surfactants are commonly nonionic surfactants such as polysorbates and poloxamers which have cloud points below 121 C i.e. they will phase invert at autoclavation temperature. Older literature teaches us that the cloud point can be elevated by the addition of e.g. PEG400 PEG3350 and some lecithins. This was in a later study applied to suspensions with ethyl diatrizoate nanocrystalline suspensions that could be stream autoclaved if the media was added cloud point boosters to bring it to approximately 135 C. Colleges from Pfizer have at conferences presented data suggesting that they occasionally see similar trend for some compound however slides have not been shared for further analysis.
This project aligns closely with Quality by Design (QbD) principles emphasizing risk assessment process understanding and robust design space development. A successful outcome of this project will provide pharmaceutical scientists with the tools to improve the physical stability of aqueous suspensions and if fully successful extend the applicability of terminal sterilization of parenteral suspensions thus improving product quality regulatory compliance and patient safety. By overcoming formulation barriers to terminal sterilization this project has the potential to significantly impact the field of sterile pharmaceutical manufacturing offering both clinical and economic benefits across the product lifecycle.
Qualifications
For further information about the position please contact Professor René Holm ().
Our vision is to create and apply knowledge across the natural sciences. We are unique in housing research within physics chemistry and pharmacy under one department which provides excellent opportunities to explore the intersections between these disciplines.
Read more aboutthePh.D. program at the Department.
Applicationsalaryetc.
Appointment as a PhD Research Fellow is for three years. Employment stops automatically at the end of the period.
The successful applicant will be employedin accordance withthe agreement on salaried PhD scholars between the Ministry of Finance and AC (the Danish Confederation of Professional Associations). Please check links for more information onsalary(only available in Danish)andtaxation.
The successful candidate will be enrolled at this universityin accordance withfaculty regulations and the Danish Ministerial Order on the PhDProgrammeat the Universities (PhD order).
Further information about thePhD-studycan be found at theUniversitys website.
The University wishes our staff to reflect the diversity of society and thus welcomes applications from all qualified candidates regardless of personal background.
Application must be in English and made in the form of a Declaration of Interest including the following:
Incomplete applications and applications received after the deadline will neither be considered nor evaluated.
Shortlisting may be used as part of the assessment process and an interview may be included in the overall evaluation of the applicants qualifications.
Applications must be submitted electronically using the link Apply now. Attached files must be in Adobe PDF format. We strongly recommend that you read How to apply for a position at SDU before you apply.
Since not all members of the appointment committee are Danish-speaking it is recommended that your application is submitted in English.
The University wishes our staff to reflect the diversity of society and thus welcomes applications from all qualified candidates regardless of personal background.
Application deadline: 26 December 2025
Starting date: 01 February 2026 or as soon as possible thereafter.
The University of Southern Denmark was established to create value for and with society. Whether our contributions come in the form of excellent research, innovative solutions, education or learning, we must make a positive difference to society and contribute to a sustainable future. ... View more